Rezolute intends to commence Phase 2b study for RZ358 later this year, in conjunction with its recent completion of a $45 million investment round. XOMA received a $2.9 million milestone payment related to the completed financing.
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
